Back to Search
Start Over
MFAP2 promotes HSCs activation through FBN1/TGF‐β/Smad3 pathway.
- Source :
- Journal of Cellular & Molecular Medicine; Nov2023, Vol. 27 Issue 21, p3235-3246, 12p
- Publication Year :
- 2023
-
Abstract
- Liver fibrosis is a chronic inflammatory process characterized by the accumulation of extracellular matrix (ECM), which contributes to cirrhosis and hepatocellular carcinoma. Increasing evidence suggests that the activation of hepatic stellate cells (HSCs) under an inflammatory state leads to the secretion of collagens, which can cause cirrhosis. In this study, we analysed data from the Gene Expression Omnibus (GEO) databases to identify differentially expressed genes (DEGs) between quiescent and fibrotic HSCs. We found that Microfibril Associated Protein 2 (MFAP2) was elevated in carbon tetrachloride (CCl4)‐induced liver fibrosis and Transforming Growth Factor‐Beta 1 (TGF‐β1)‐activated HSCs. Knockdown of MFAP2 inhibited HSC proliferation and partially attenuated TGF‐β‐stimulated fibrogenesis markers. Bioinformatics analysis revealed that Fibrillin‐1 (FBN1) was correlated with MFAP2, and the expression of FBN1 was significantly upregulated after MFAP2 overexpression. Silencing MFAP2 partially attenuated the activation of HSCs by inhibiting HSC proliferation and decreasing collagen deposits. In vitro results showed that the inhibition of MFAP2 alleviated hepatic fibrosis by inhibiting the activation and inducing the apoptosis of active HSCs in a CCl4‐induced mouse model. In conclusion, our results suggest that MFAP2 is a potential target for the clinical treatment of liver fibrosis. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15821838
- Volume :
- 27
- Issue :
- 21
- Database :
- Complementary Index
- Journal :
- Journal of Cellular & Molecular Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 173438332
- Full Text :
- https://doi.org/10.1111/jcmm.17884